



Review

Endogenous Opiates and Behavior: 2015



Richard J. Bodnar

Department of Psychology and Neuropsychology Doctoral Sub-Program, Queens College, City University of New York, Flushing, NY 11367, United States

ARTICLE INFO

Article history:

Received 26 September 2016

Received in revised form 8 December 2016

Accepted 10 December 2016

Available online 22 December 2016

Keywords:

Mu opioid receptor
 Delta opioid receptor
 Kappa opioid receptor
 ORL-1 receptor
 Enkephalins
 Beta-endorphin
 Endomorphins
 Nociception
 Morphine
 Naloxone

ABSTRACT

This paper is the thirty-eighth consecutive installment of the annual review of research concerning the endogenous opioid system. It summarizes papers published during 2015 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides, opioid receptors, opioid agonists and opioid antagonists. The particular topics that continue to be covered include the molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors related to behavior, and the roles of these opioid peptides and receptors in pain and analgesia, stress and social status, tolerance and dependence, learning and memory, eating and drinking, drug abuse and alcohol, sexual activity and hormones, pregnancy, development and endocrinology, mental illness and mood, seizures and neurologic disorders, electrical-related activity and neurophysiology, general activity and locomotion, gastrointestinal, renal and hepatic functions, cardiovascular responses, respiration and thermoregulation, and immunological responses.

© 2016 Elsevier Inc. All rights reserved.

Contents

1. Introduction	128
2. Endogenous opioids and receptors	128
2.1. Molecular-biochemical effects of mu agonists and receptors	128
2.2. Molecular-biochemical effects of delta agonists and receptors	130

Abbreviations: Ach, acetylcholine; ACL, anterior cruciate ligament; ACTH, adrenocorticotrophic hormone; AMP, adenosine monophosphate; AMPK, 5'adenosine monophosphate-activated protein kinase; AS ODN, antisense oligonucleotide; BDNF, brain-derived neurotrophic factor; BEND, beta-endorphin; BFNA, beta-funaltrexamine; BNST, bed nucleus of the stria terminalis; Ca(2+), calcium; CART, cocaine and amphetamine-regulated transcript; CB, cannabinoid; CCK, cholecystokinin; CFA, complete Freund's adjuvant; ChAT, choline acetyltransferase; CO, carbon monoxide; COX, cyclooxygenase; C/P, caudate/putamen; CREB, Ca(2+)/cAMP responsive element binding protein; CRF, corticotropin factor; CSF, cerebrospinal fluid; DA, dopamine; DADL, D-Ala(2), D-Leu (5)-enkephalin; DAMGO, D-Ala(2), Nme(4), Gly-ol (5)-enkephalin; Delt, deltorphin; DOR, delta opioid receptor; DPDPE, D-Pen(2) D-Pen(5)-enkephalin; DREAM, downstream regulatory element antagonistic modulator; DRG, dorsal root ganglion; DYN, Dynorphin; Enk, enkephalin; Enk, enkephalin; ENT, ear nose and throat; EPSP, excitatory post-synaptic potential; ERK, extracellular regulated signal kinases; GI, gastrointestinal; GIRK, G-protein inwardly rectifying K+ channel subunit; GnRH, gonadotropin-releasing hormone; GPCR, G protein coupled receptor; HIV, human immunodeficiency virus; HR, heart rate; ICSS, intracranial self-stimulation; IL, interleukin; IPSC, inhibitory post-synaptic currents; K(+), potassium; KO, knockout; KNDy, kisspeptin-neurokinin B-dynorphin; KOR, kappa opioid receptor; LC, locus coeruleus; Lenk, leu-enkephalin; LH, leutinizing hormone; L-NAME, N(omega)-nitro-L-arginine methyl ester; LPS, lipopolysaccharide; LTP, long-term potentiation; M3G, morphine-3-glucuronide; M6G, morphine-6-glucuronide; MAP, mean arterial pressure; MAPK, mitogen-activated protein kinase; Menk, met-enkephalin; 6MAM, 6-monoacetylmorphine; MOR, mu opioid receptor; mPFC, medial prefrontal cortex; MPOA, medial preoptic area; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NAC, nucleus accumbens; NBNI, nor-binaltorphamine; NE, norepinephrine; NMDA, N-methyl-D-aspartate; NO, nitric oxide; NOS, nitric oxide synthase; NPY, neuropeptide Y; NSAID, non-steroidal anti-inflammatory drug; NTI, naltrindole; NTS, nucleus tractus solitarius; OPRD-1, delta opioid receptor gene; OPRM1, mu opioid receptor gene; OFQ/N, nociceptin; ORL-1, orphan receptor like receptor; 6-OHDA, 6-hydroxydopamine; PAG, periaqueductal gray; PBN, parabrachial nucleus; PCA, patient-controlled analgesia; PDYN, pro-dynorphin; Penk, pro-enkephalin; PKA, protein kinase A; PKC, protein kinase C; POMC, pro-opiomelanocortin; PTSD, post-traumatic stress disorder; PVN, paraventricular nucleus; QTL, quantitative trait loci; RVM, rostral ventromedial medulla; 5-HT, serotonin; SIV, simian immunodeficiency virus; SN, substantia nigra; SNP, single nucleotide polymorphism; SON, supraoptic nucleus; SP, substance P; STZ, streptozotocin; TH, tyrosine hydroxylase; THC, tetrahydrocannabinol; TMS, transcranial magnetic stimulation; TNF, tumor necrosis factor; TP, testosterone propionate; TRPV1, transient receptor potential vanilloid subfamily member 1; VIP, vasoactive intestinal polypeptide; VTA, ventral tegmental area.

E-mail address: richard.bodnar@qc.cuny.edu<http://dx.doi.org/10.1016/j.peptides.2016.12.004>

0196-9781/© 2016 Elsevier Inc. All rights reserved.

2.3.	Molecular-biochemical effects of kappa agonists and receptors	130
2.4.	Molecular-biochemical effects of OFQ/N and ORL-1 receptor	130
2.5.	Neuroanatomical localization of mu agonists and receptors	131
2.6.	Neuroanatomical localization of delta agonists and receptors	131
2.7.	Neuroanatomical localization of kappa agonists and receptors	131
2.8.	Neuroanatomical localization of OFQ/N and ORL-1 receptor	131
3.	Pain and opioid analgesia in animal models	131
3.1.	Morphine	131
3.2.	Mu opioid agonists	132
3.3.	Mu opiate agonists	132
3.4.	Endomorphins	133
3.5.	Bend	133
3.6.	Manipulations affecting mu analgesia	133
3.7.	Mu receptors	133
3.8.	Delta agonists and receptors	133
3.9.	Kappa agonists and receptors	134
3.10.	OFQ/N and ORL-1 receptor	134
3.11.	Sex, age and genetic differences	134
4.	Pain and opioid analgesia in human studies	134
4.1.	Volunteers	134
4.2.	Dental pain	134
4.3.	Chronic and emergency pain	134
4.4.	Cancer pain	135
4.5.	Surgical pain	136
4.6.	Caesarean and hysterectomy pain	139
5.	Opioid mediation of other analgesic responses	139
5.1.	Opioid-sensitive analgesic responses	139
5.2.	Opioid-insensitive analgesic responses	140
6.	Stress and social status	140
6.1.	Stress-induced and conditioned placebo analgesia	140
6.2.	Emotional responses in opioid-mediated behaviors	140
6.3.	Opioid involvement in stress response regulation	141
7.	Opioid tolerance and dependence	141
7.1.	Cellular effects on morphine tolerance	141
7.2.	Organismic effects on morphine tolerance	141
7.3.	Opioid effects on morphine tolerance	141
7.4.	Peptide-transmitter effects on morphine tolerance	141
7.5.	Other forms of opioid tolerance	142
7.6.	Cellular effects on morphine dependence and withdrawal responses	142
7.7.	Organismic effects on morphine dependence and withdrawal responses	142
7.8.	Opioid effects on morphine dependence and withdrawal responses	142
7.9.	Peptide-transmitter effects on morphine dependence and withdrawal responses	142
8.	Learning and memory	143
8.1.	Opiates and conditioned place preferences (CPP) and reward	143
8.2.	Non-opioid effects on opioid CPP	143
8.3.	Opioid effects on non-opioid CPP	143
8.4.	Opiates and conditioned aversion paradigms	143
8.5.	Opiates and drug discrimination and spatial learning	143
8.6.	Opiates and memory	144
9.	Eating and drinking	144
9.1.	Opioid agonists and ingestive behavior	144
9.2.	Opioid antagonists and ingestive behavior	144
9.3.	POMC and opioid genes and ingestion	145
10.	Drugs of abuse and alcohol	145
10.1.	Opiates and animal self-administration studies	145
10.2.	Opiates and human addiction studies	145
10.3.	Opiates and ethanol: animal behavioral models	147
10.4.	Opiates and ethanol: ethanol-induced changes in opioid systems	148
10.5.	Opiates and ethanol: human studies	148
10.6.	Opiates and THC	148
10.7.	Opiates and stimulants: animal behavioral studies	148
10.8.	Opiates and stimulants: anatomical, molecular and neurochemical studies	148
10.9.	Opiates and stimulants: human studies	148
10.10.	Opiates and other drug abuse classes	148
11.	Sexual activity and hormones, pregnancy, development and endocrinology	149
11.1.	Sexual activity and hormones	149
11.2.	Pregnancy	149
11.3.	Development	149
11.4.	Endocrinology	149
12.	Mental illness and mood	149
12.1.	Mental illness	149
12.2.	Mood	150

Download English Version:

<https://daneshyari.com/en/article/5514679>

Download Persian Version:

<https://daneshyari.com/article/5514679>

[Daneshyari.com](https://daneshyari.com)